According to the latest official announcement from the U.S. Food and Drug Administration (US FDA), Everlight Chemical’s API plant has successfully passed its 2025 routine on-site inspection.
Excellence in Quality, Global Presence
Everlight Chemical’s Pharmaceutical Business Unit has long been dedicated to the R&D and manufacturing of high-entry-barrier APIs, particularly the Prostaglandins series, known for its highly challenging synthetic processes. This successful US FDA inspection not only solidifies our leading supply position in the North American market but also provides the most robust regulatory assurance for global pharmaceutical clients in New Drug Development and CDMO services.
We remain committed to our core value of “Integrity,” internalizing international regulations into our daily operational standards to be the most reliable strategic API partner for the global pharmaceutical industry.